Top 10 Pharmacy Benefit Managers Shaping US Access 2026
Three companies process 80% of all US prescription claims — here’s the full PBM and market access landscape hospital pharmacy teams need to know.
Three is still the magic number in pharmacy benefits. For 2025, roughly 80% of all equivalent prescription claims in the US were processed by just three companies. But the market beneath that concentration is shifting fast — driven by transparency demands, legislative scrutiny, and a growing wave of “cost-plus” pass-through PBM alternatives. Here’s the landscape hospital pharmacy and market access teams need to track in 2026.
1. CVS Caremark
The pharmacy benefit management arm of CVS Health, and one of the “Big Three” processing the majority of US prescription claims. In February 2026, CVS Caremark rolled out touchless prior authorization for specialty drugs using the Surescripts platform, aimed at speeding approvals and patient access.
2. Express Scripts (Cigna)
Cigna’s PBM business remains one of the three dominant players nationally, though it has drawn direct regulatory scrutiny — the FTC settled a lawsuit with Express Scripts over allegations it manipulated insulin pricing and impeded patient access.
3. Optum Rx (UnitedHealth Group)
Completing the “Big Three,” Optum Rx became the first major PBM to launch a fee-based pharmacy care program in May 2026, aimed at increasing pricing transparency and affordability — a notable shift given the traditional spread-pricing model dominating the sector.
4. Prime Therapeutics
A significant national PBM player named consistently alongside the Big Three in market coverage analyses, serving a substantial share of health plan and employer clients outside the three dominant networks.
5. MedImpact Healthcare Systems
The largest independent pharmacy benefit solutions company in the US, investing heavily in clinical programs, technology, and operations as an alternative to the vertically integrated Big Three.
6. Navitus Health Solutions
A URAC-accredited, zero-spread, full pass-through PBM that aligns performance directly with plan sponsors’ benefit goals — part of the growing transparent-PBM segment gaining traction against traditional spread-pricing models.
7. Abarca / LucyRx
Following a reported merger between Abarca and LucyRx, this combination signals continued consolidation activity among mid-market and transparency-focused PBMs positioning against the dominant three.
8. Judi Rx
Founded in 2018 with an explicit mission to redefine PBM transparency, Judi Rx positions itself as a pharmacy care services company rather than a traditional claims processor, targeting sponsors seeking financial alignment.
9. Capital Rx
A technology-forward PBM built around its proprietary claims adjudication platform, part of the broader shift toward digitally native, transparency-first PBM models challenging legacy infrastructure.
10. Regional & Non-Traditional PBMs
A growing tier of smaller, transparent PBMs — highlighted specifically in recent market overviews as having increasing impact despite operating outside the top-line market share figures — worth monitoring as consolidation and transparency pressure reshape the mid-market.
What This Means for Access & Formulary Teams
Concentration creates both leverage and risk. With 80% of claims running through three companies, formulary and contracting decisions at CVS Caremark, Express Scripts, and Optum Rx have outsized influence on national access — but that concentration also means regulatory or legal action against any one player can ripple across the entire market quickly.
Transparency pressure is reshaping vendor selection. The rise of zero-spread, full pass-through PBMs signals sponsors are increasingly willing to trade the scale of the Big Three for pricing clarity — a genuine shift worth factoring into any PBM RFP process in 2026.
Biosimilars are now a formulary strategy, not a footnote. With the large majority of PBMs actively leveraging specialty biosimilars to manage cost and utilization, formulary teams should expect biosimilar positioning to be a standard negotiating lever going forward, not an edge case.
FAQ
What percentage of US prescriptions do the top 3 PBMs control?
Roughly 80% of equivalent prescription claims are processed by CVS Caremark, Express Scripts (Cigna), and Optum Rx (UnitedHealth) combined.
What is a “pass-through” or “transparent” PBM?
A pass-through PBM passes negotiated drug costs directly to the plan sponsor without retaining a spread between what it pays and charges, aligning PBM compensation more directly with cost outcomes rather than rebate volume.
Why are PBMs facing increased regulatory scrutiny?
PBMs have come under sustained policy attention for their role in drug pricing, including FTC action and ongoing legislative proposals targeting transparency and spread-pricing practices.
Sources
- Drug Channels, The Top Pharmacy Benefit Managers of 2025
- Transpire Insight, Top 25 Pharmacy Benefit Management Companies
- Shortlister, Best PBM Companies 2026
- Access Market Intelligence, Pharmacy Benefit Managers 2026 Overview
- HIRC, Pharmacy Benefit Managers Market Landscape and Strategic Imperatives